Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits
- 1 January 2002
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 303 (3) , 993-1000
- https://doi.org/10.1124/jpet.102.040089
Abstract
DPC423 [1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide] is a synthetic, competitive, and selective inhibitor of coagulation factor Xa (fXa) (Ki: 0.15 nM in humans, 0.3 nM in rabbit). The objective of this study was to compare effects of DPC423, enoxaparin (low-molecular-weight heparin), and argatroban (thrombin inhibitor) on arterial thrombosis and hemostasis in rabbit models of electrically induced carotid artery thrombosis and cuticle bleeding, respectively. Compounds were infused i.v. continuously from 60 min before artery injury or cuticle transection to the end of experiment. Carotid blood flow was used as a marker of antithrombotic effect. Antithrombotic ED50 values were 0.4 mg/kg/h for enoxaparin (n = 6), 0.13 mg/kg/h for argatroban (n = 6), and 0.6 mg/kg/h for DPC423 (n = 12). DPC423 at the maximum antithrombotic dose increased activated partial thromboplastin time and prothrombin time (n = 6) by 1.8 ± 0.07- and 1.8 ± 0.13-fold, respectively, without changes in thrombin time and ex vivo thrombin activity. The antithrombotic effect of DPC423 was significantly correlated with its ex vivo anti-fXa activity (r = 0.86). DPC423 at 1, 3, and 10 mg/kg p.o. increased carotid blood flow (percent control) at 45 min to 10 ± 4, 24 ± 6, and 74 ± 7, respectively (n= 6/group). Cuticle bleeding times (percent change over control) determined at the maximum antithrombotic dose were 88 ± 12 for argatroban, 69 ± 13 for heparin, 4 ± 3 for enoxaparin, 5 ± 4 for DPC423, and −3 ± 2 for the vehicle (n = 5–6/group), suggesting dissociation of antithrombotic and bleeding time effects for DPC423 and enoxaparin. The combination of aspirin and DPC423 at ineffective antithrombotic doses produced significant antithrombotic effect. Therefore, these results suggest that DPC423 is a clinically useful oral anticoagulant for the prevention of arterial thrombosis.Keywords
This publication has 29 references indexed in Scilit:
- First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary DiseaseCirculation, 2002
- Effects of ZK-807834, a Novel Inhibitor of Factor Xa, on Arterial and Venous Thrombosis in RabbitsJournal of Cardiovascular Pharmacology, 2000
- AspirinCirculation, 2000
- Antithrombotic Efficacy of a Novel Murine Antihuman Factor IX Antibody in RatsArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Antithrombotic Efficacy of the Vitamin K Antagonist Fluindione in a Human Ex Vivo Model of Arterial ThrombosisArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Synthetic Inhibitors of Thrombin and Factor Xa: From Bench to BedsideThrombosis Research, 1999
- The Antiaggregating and Antithrombotic Activity of Clopidogrel Is Potentiated by Aspirin in Several Experimental Models in the RabbitThrombosis and Haemostasis, 1998
- Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitorThrombosis Research, 1995
- The coagulation cascade: initiation, maintenance, and regulationBiochemistry, 1991
- A canine model of hemophilic (factor VIII:C deficiency) bleedingBlood, 1982